| Indicators | Browse All

Surrozen, Inc. (SRZN)

Healthcare | Biotechnology | South San Francisco, United States | NasdaqCM
22.42 USD -1.59 (-6.622%) ⇩ (Aug. 28, 2026, 4 p.m. EDT)
After hours: 22.42

Short-term:★★⯪☆☆Long-term:★☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | Aug. 22, 2026, 5:43 a.m. EDT

The immediate outlook is neutral-to-slightly-bearish due to a lack of clear directional momentum and a statistically weak short-term forecast, despite the stock hovering near key resistance levels. However, the long-term investment case is severely compromised by a catastrophic multi-year price collapse; the asset has lost nearly 90% of its value over the last four years, with three consecutive years of negative annual returns ending just recently. While the most recent year showed a sharp recovery, the persistent structural decline and deteriorating fundamentals—evidenced by negative earnings, negative operating margins, and negative book value—indicate a business struggling to generate sustainable value. There is no dividend income to offset these risks, making this a high-risk speculative vehicle rather than a viable core holding.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.077893
AutoARIMA0.080349
AutoETS0.080350
AutoTheta0.106083

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 39%
H-stat 0.20
Ljung-Box p 0.000
Jarque-Bera p 0.405
Excess Kurtosis -0.14
Attribute Value
Sector Healthcare
Revenue per Share 1.142
Market Cap 263,514,768
Forward P/E -5.36
Beta 0.56
Previous Name Consonance-HFW Acquisition Corp.
Website https://www.surrozen.com

Info Dump

Attribute Value
52 Week Change 0.9488636
Address1 171 Oyster Point Boulevard
Address2 Suite 400
All Time High 210.0
All Time Low 4.5
Ask 29.31
Ask Size 2
Average Analyst Rating 1.0 - Strong Buy
Average Daily Volume10 Day 178,460
Average Daily Volume3 Month 203,472
Average Volume 203,472
Average Volume10Days 178,460
Beta 0.559
Bid 16.85
Bid Size 2
Book Value -18.603
City South San Francisco
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 22.42
Current Ratio 12.141
Custom Price Alert Confidence HIGH
Date Short Interest 1,786,665,600
Day High 23.6
Day Low 22.15
Display Name Surrozen
Earnings Quarterly Growth 0.262
Earnings Timestamp End 1,746,821,116
Earnings Timestamp Start 1,746,821,116
Ebitda -44,128,000
Ebitda Margins 0.0
Enterprise To Ebitda -3.802
Enterprise To Revenue 14.577
Enterprise Value 167,791,776
Eps Current Year -9.14
Eps Forward -4.18667
Eps Trailing Twelve Months -37.41
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 23.1278
Fifty Day Average Change -0.7077999
Fifty Day Average Change Percent -0.030603858
Fifty Two Week Change Percent 94.88636
Fifty Two Week High 35.0
Fifty Two Week High Change -12.58
Fifty Two Week High Change Percent -0.35942855
Fifty Two Week Low 11.25
Fifty Two Week Low Change 11.17
Fifty Two Week Low Change Percent 0.99288887
Fifty Two Week Range 11.25 - 35.0
Financial Currency USD
First Trade Date Milliseconds 1,610,375,400,000
Float Shares 4,617,855
Forward Eps -4.18667
Forward P E -5.3550916
Free Cashflow -21,751,750
Full Exchange Name NasdaqCM
Full Time Employees 44
Fullday Change -1.59
Fullday Change Percent -6.62224
Fullday Price 22.42
Gmt Off Set Milliseconds -14,400,000
Gross Margins -2.00382
Gross Profits -23,066,000
Has Pre Post Market Data 1
Held Percent Insiders 0.03137
Held Percent Institutions 1.04852
Implied Shares Outstanding 11,753,558
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,021-08-12
Is Earnings Date Estimate 0
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,702,512,000
Last Split Factor 1:15
Long Business Summary Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Long Name Surrozen, Inc.
Market us_market
Market Cap 263,514,768
Market State CLOSED
Max Age 86,400
Message Board Id finmb_401948183
Most Recent Quarter 1,782,777,600
Name Change Date 2,026-08-28
Net Income To Common -324,564,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 282,202,927
Number Of Analyst Opinions 5
Open 23.52
Operating Cashflow -34,762,000
Operating Margins -2.074
Payout Ratio 0.0
Phone 650 489 9000
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 22.42
Post Market Time 1,787,947,805
Prev Name Consonance-HFW Acquisition Corp.
Previous Close 24.01
Price Eps Current Year -2.452954
Price Hint 2
Price To Book -1.205182
Price To Sales Trailing12 Months 22.892431
Profit Margins 0.0
Quick Ratio 11.879
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.0
Region US
Regular Market Change -1.59
Regular Market Change Percent -6.62224
Regular Market Day High 23.6
Regular Market Day Low 22.15
Regular Market Day Range 22.15 - 23.6
Regular Market Open 23.52
Regular Market Previous Close 24.01
Regular Market Price 22.42
Regular Market Time 1,787,947,200
Regular Market Volume 239,362
Return On Assets -0.25395
Revenue Growth 4.086
Revenue Per Share 1.142
Sand P52 Week Change 0.20504117
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 11,753,558
Shares Percent Shares Out 0.1066
Shares Short 1,253,140
Shares Short Previous Month Date 1,784,073,600
Shares Short Prior Month 970,957
Short Name Surrozen, Inc.
Short Percent Of Float 0.192
Short Ratio 4.68
Source Interval 15
State CA
Symbol SRZN
Target High Price 51.0
Target Low Price 40.0
Target Mean Price 44.6
Target Median Price 44.0
Total Cash 102,039,000
Total Cash Per Share 8.682
Total Debt 6,316,000
Total Revenue 11,511,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -37.41
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 23.781836
Two Hundred Day Average Change -1.3618355
Two Hundred Day Average Change Percent -0.057263684
Type Disp Equity
Volume 239,362
Website https://www.surrozen.com
Zip 94,080